Patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma experienced a better overall survival when treated with adjuvant chemotherapy.

Investigators reported that combining a blood-based biomarker panel with PLCOm2012 resulted in a significant improvement in risk assessment for lung cancer screenings.

Fam-trastuzumab deruxtecan-nxki, which was granted a priority review designation, appears to have potential for patients with HER2-positive metastatic breast cancer.

Women diagnosed with ovarian cancer were reported to have longer waiting times for treatment vs other cancer types with the exception of kidney cancer.

Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.

Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.

Neeraj Agarwal, MD, and Simon Chowdhury, MD, comment on the secondary end points from the final analysis of the TITAN trial.

Lindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.

Patients with breast cancer who were treated at a community-based oncology practice that used routine depression screening were more likely to a receive referral for behavioral care vs those in an education-only cohort.

CancerNetwork® spoke with Rafael Fonseca, MD, about findings from a simulation using real-world data sets to compare the utility of daratumumab-containing regimens as either frontline or second-line therapy.